Mr Thomas Boon Leong Lam: Urology

Home
Mr Thomas Boon Leong Lam

Fee assured
Verified this account

Overview

COVID-19

This healthcare professional is currently treating patients. Please speak to them to find out more about their availability.

Last updated: 12 Nov 2020

Specialises in

Benign Prostate disorders

General urology

Urological oncology

About me

Mr. Thomas Lam is Consultant Urological Surgeon and Honorary Senior Clinical Lecturer based at the Department of Urology, Aberdeen Royal Infirmary, and Academic Urology Unit, University of Aberdeen, Scotland. He has a sub-specialist interest in prostate cancer and in robotic radical prostatectomy. Academically, his main areas of interest include clinical trials, evidence-based medicine, evidence synthesis and meta-analysis, clinical practice guideline development, core outcome sets in urological conditions, and methods research. He has published extensively in his areas of interest, having authored more than 200 peer-reviewed publications. He is heavily involved in the development and production of European Association of Urology Clinical Practice Guidelines which issues guidelines to urologists around the world, being a senior panel member of the EAU Prostate Cancer Guideline Panel and EAU Renal Cell Cancer Guideline Panel. He also has a strong track record in undergraduate and postgraduate training and education, being an educational supervisor for medical students, FY2 and CT doctors, and supervisor for PhD and MD students.

Areas of interest

Robotic radical prostatectomy, urinary incontinence, benign prostatic disease, urinary tract infections, painful bladder syndrome

Medical secretaries

Linda Smith
Department of Urology Aberdeen Royal Infirmary Cornhill Road ABERDEEN AB25 2ZN
01224 553417
lindasmith1@nhs.net

Anaesthetists worked with

Mr Thomas Boon Leong Lam has worked with Dr Ratnasabapathy Kumar at the following hospitals:
- BMI Albyn Hospital (1-5)

About me

Current NHS consultant posts held

Consultant Urological Surgeon, Department of Urology, Ward 209, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN.

Research interests

1) Urological cancers including kidney, prostate, bladder, penile and urothelial cancers;
2) Evidence synthesis and meta-analysis;
3) Guideline development;
4) Clinical trials and trial methodology;
5) Methods research;
6) Core outcome set development

Personal interests

Music, sprint triathlon, computing, high fidelity and high definition music, home cinema

(Additional) Languages spoken

Publications

Lam TBL, MacLennan S, Willemse PPM, et al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). Eur Urol. 2019 (in press).

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol. 2019 Aug;76(2):151-156.

Van den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, De Santis M, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Mason M, Moris L, Schoots IG, van der Kwast T, van der Poel H, Wiegel T, Willemse PM, Rouvière O, Lam TB, Mottet N. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30159-2.

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH, Hofmann F, Kuczyk MA, Lam TB, et al. Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. Eur Urol Oncol. 2019 Jun 3. pii: S2588-9311(19)30054-9.

Lam TBL, MacLennan S, Plass K, et al. Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. European Urology. 2019 Apr;75(4):699-702. doi: 10.1016/j.eururo.2018.11.009. Epub 2018 Nov 22.

Van den Broeck T, Mottet N, Lam T. Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.10.011. European Urology. 2019 Apr 6. pii: S0302-2838(19)30255-6.

Courses offered to GPs

Prostate cancer management; benign prostatic disorders; urological infections; management of overactive bladder syndrome.

My qualifications & training

My private practice

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

M4514
Endoscopic examination of bladder (rigid cystoscopy) including any biopsy - (1-5)

BMI Albyn Hospital (1-5)
M4510
Diagnostic endoscopic examination of bladder (flexible cystoscopy) including any biopsy - (1-5)

BMI Albyn Hospital (1-5)
M5630
Therapeutic injection into bladder neck for treatment of stress incontinence (peri-urethral bulking agents) (including cystoscopy) - (1-5)

BMI Albyn Hospital (1-5)
M4320
Endoscopic hydrostatic distension of bladder (including cystoscopy) - (1-5)

BMI Albyn Hospital (1-5)
N3030
Circumcision - (1-5)

BMI Albyn Hospital (1-5)

Report this page

Finder

Covid-19

Note: